Introduction
Medications for type 2 diabetes with low risk of hypoglycemia are especially important in the setting of multiple coexisting chronic diseases (multimorbidity) and advanced age. The risks of hypoglycemia and adverse drug events (ADEs) are amplified in the older adults by myriad diabetic complications: chronic kidney disease affecting drug clearance, stroke and peripheral neuropathy affecting manual dexterity, physical ability and cognition, and diabetic retinopathy affecting proper dosing of insulin. 1, 2 Higher rates of complications and mortality are associated with both longer duration of disease and greater age, as well as coexistence of multiple chronic diseases. 3 When diabetes coexist with multiple chronic diseases such as Alzheimer's and Parkinson's disease in an older adults, the risk of serious hypoglycemia is further heightened by exposure to multiple medications (polypharmacy), age-related change in drug metabolism and sensory function, and suboptimal adherence to diet and medications. Hypoglycemic events place older adults with diabetes at greater risk for falls, fractures, depression, cardiac arrhythmias and other cardiac events, dementia, and
The mechanism of action of GLP-1 RAs in diabetes has been well documented in both human and animal studies. [12] [13] [14] Briefly, the gastrointestinal tract releases GLP-1 when food is ingested. GLP-1 receptor agonists stimulate GLP-1 receptors expressed on pancreatic islet beta cells, but also those expressed in cells in multiple systems, thus potentially explaining the other beneficial effects of GLP-1 RAs, 12, 13 as discussed below and presented in Table 1 . The use of GLP-1 RAs is associated primarily with dose-related gastrointestinal side effects (nausea, diarrhea, vomiting), and is not indicated in patients at risk for pancreatitis or kidney disease. 55 Despite these contraindications, a recent meta-analysis (n = 4330) found GLP-1 receptor agonists superior to alternative incretin-based therapy, dipeptidyl peptidase-4 (DPP-4) inhibitors, in reducing hemoglobin A1c (HbA1c). 56 
Methodology of evidence review
The primary aim of the current review was to characterize the secondary effects of GLP-1 RAs that may be relevant to clinically complex older adults with diabetes and multimorbidity, in whom polypharmacy is a concern. 57, 58 In September 2017, a PubMed search was conducted for relevant terms, including glucagon-like peptide-1 receptor agonists, exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, and semaglutide, and suspected secondary effects (e.g. exenatide + cardiovascular); a search of cited and related articles was done in PubMed and Google Scholar. Sources were examined until no new human studies were found. The relevance of each reference was discussed until consensus was obtained. Animal studies were included when human studies were missing. Expert opinion was included when deemed relevant by the authors. A summary of results (Table 1) was developed using previous guides. 54, 57 Drugs were evaluated based on the effect on a secondary system (i.e. blood lipids, hypertension, liver, brain, etc.) and effects refined as indicated. Levels of Evidence for Therapy/Prevention/Etiology/Harm: 1a, Systematic reviews (with homogeneity) of randomized controlled trials (RCTs); 1b: Individual RCTs (with narrow confidence interval); 1c: Allor-none RCTs; 2a: Systematic reviews (with homogeneity) of cohort studies; 2b: Individual cohort study or low quality RCTs (e.g. <80% follow-up); 2c: 'Outcomes' Research; ecological studies; 3a: Systematic review (with homogeneity) of case-control studies; 3b: Individual case-control study; 4: Case-series (and poor quality cohort and case-control studies); and 5: Expert opinion without explicit critical appraisal, or based on physiology, bench research or 'first principles'. 54 
Secondary effects and mechanism of action of GLP-1RAs on comorbidities: evidence from clinical and basic science research

Effects on the cardiovascular system
The effect of GLP-1 receptor agonists on triglyceride, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) levels has been evaluated in multiple studies.
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5:Expert opinion without explicit critical appraisal, or based on physiology, bench research or 'first principles'. In the meta-analysis by Sun and colleagues, 35 trials were analyzed for the effects of exenatide, liraglutide, or taspoglutide on lipid profile. 14 GLP-1 agonist therapy was associated with modest decreases in LDL-C, triglycerides, and total cholesterol, but no significant effect on HDL-C. Compared with placebo, the GLP-1 agonist group demonstrated a reduction in LDL-C from −0.08 mmol/L to −0.16 mmol/L. 14 Exenatide, liraglutide, and taspoglutide treatment led to a decrease in total cholesterol, while liraglutide and taspoglutide led to a reduction in triglyceride levels. 14 Other studies showed a reduction in one or more lipid levels with exenatide or liraglutide. 19, 20 Hypertension, found in 30-70% of those with type 2 diabetes, is a well-known risk factor for both cardiovascular and cerebrovascular disease. 24 The mechanisms for the antihypertensive effects of GLP-1 RAs include a reduction in the risk of left ventricular hypertrophy, an increase in sodium excretion and increased atrial natriuretic peptide (ANP) secretion, leading to reduced blood pressure (BP). 22 Indeed, GLP-1 receptordeficit mice secreted no ANP when given GLP-1 RAs, indicating a putative BP-regulating pathway via a gut-heart GLP-1 receptor-dependent and ANP-dependent axis. 22 In humans, Zhao found strong evidence from clinical and preclinical studies that GLP-1 RA treatment can benefit patients with myocardial ischemia and heart failure. 22 29 In an open-labelled RCT of 45 patients with PD, a mean improvement of 1.8 points in the Mattis dementia rating scale, was observed at 24 months in patients treated with exenatide, compared with a mean deterioration of 3.5 in the control group. 28 Similarly, in a single center, double-blind, randomized placebo-controlled 60-week trial with 62 participants, 30 the exenatide group had MDS-UPDRS scores 3.5 points lower than the placebo group. This improvement in severity of PD motor systems persisted for 48 weeks of treatment and through
journals.sagepub.com/home/taj 13 the 2-week wash-out period. 20 These results are considered 'proof of concept' rather than 'proof of efficacy,' and larger and longer RCT studies are needed to confirm these findings. 86 Alzheimer's disease. Impairment of short-term or long-term memory and learning is a key symptom of Alzheimer's disease (AD), the cause of 60-80% of all cases of dementia in older adults. 87 91 and GLP-1 receptors are located widely throughout the brain. [92] [93] [94] In a 26-week, placebo-controlled double-blinded intervention (n = 38) in AD patients with longstanding diabetes, the use of liraglutide prevented the expected decline of cerebral metabolic rate for glucose uptake (using FDG-PET) in the parieto-temporal frontal and posterior cingulate cortices. 35 Clinical studies on GLP-1 RAs provide evidence of promising neuroprotective, and even regenerative, properties that may be utilized in patients with AD or PD. [28] [29] [30] [31] [32] [35] [36] [37] [38] Given further clinical evidence, they have the potential to be the therapeutic agent of choice for diabetic patients with AD. 28, 40, 89, 90 For example, in clinical trials, exenatide-treated patients showed a clear improvement in cognitive score, suggesting a beneficial effect on cognition and memory; this benefit was still visible 1 year after the trials. 28 Optimism for the benefit of GLP-1 RAs in AD has recently been dampened, however. A recent Cochrane review found no relationship between the use of diabetes medications and cognitive decline during a follow-up period of 40-60 months, 95 and a recent review of clinical treatment of diabetes in the elderly argues for a holistic approach that incorporates caregiver input, screening for geriatric syndromes, functional medicine, and periodic re-evaluation of targets and strategies. 96 Depression/mood disorders. Mood disorders (major depressive and anxiety disorders) are common coexisting chronic diseases in diabetic patients, which increase morbidity, disability, and mortality in these patients. 8 GLP-1 receptor agonists have been found to affect areas of the brain associated with emotional regulation. 97 In a metaanalysis, McIntyre and colleagues found improvement in mood and cognition with GLP-1 RAs, regardless of psychiatric diagnoses. 98 More recently, Billings and colleagues found that those taking weekly GLP1-RAs (exenatide, dulaglutide, or semaglutide) had greater health-related quality of life (i.e. improved treatment satisfaction and willingness to continue treatment) over those taking daily GLP-1 RAs; weekly semaglutide was associated with the greatest treatment satisfaction. 99 The cognitive effects of GLP-1 RAs are especially important in patients with diabetes and psychiatric comorbidities, given the high prevalence of cognitive impairment and antipsychotic related metabolic syndrome in this population. 100 In a case-controlled study of diabetic patients (n = 138), Grant and colleagues found that exenatide-treated patients had significantly reduced Hospital Anxiety and Depression Scale (HADS) scores at 6 months when compared with the insulin-treated group, indicating greater treatment satisfaction and higher wellbeing. 42 Another open labelled trial with 19 patients showed a significant increase from baseline to week 4 in scores for the Trail Making Test B (executive function), in Digit Symbol Substitution Test (DSST; executive function, speed of processing, attention) and in the Rey Auditory Verbal Learning Test (RAVLT; learning memory)/acquisition), in response to liraglutide, especially in patients with comorbid bipolar disorder (BD) or major depressive disorder (MDD) and cognitive impairment. 41 The mechanisms for the above findings have not been well described but initial studies provide some insight. Sharma and colleagues found that liraglutide reversed the behavioral depression and metabolic abnormalities (weight gain, increased blood lipids) associated with long-term atypical antipsychotic treatment in rats. 100 In another experimental rat model, Anderberg and colleagues found that liraglutide reversed the antipsychotic-induced metabolic abnormalities in rats, and that chronic injections of exenatide were neither anxiogenic nor anxiolytic, but caused a reduction in depression-like behavior. 97 The presence of GLP-1 receptor in the dorsal raphe (DR), a major area of serotonergic neurons, suggests a potential role for GLP-1 RAs in emotional processing and mood regulation. Activation of the DR-GLP-1 receptor alone is sufficient to increase anxiety-like behavior − an effect similar to findings in the initial use of selective serotonin reuptake inhibitors. 97 In summary, use of GLP-1 RAs in older multimorbid diabetes patients with depression and bipolar and other psychiatric disorders may help improve mood and cognition, while reducing the metabolic side effects of antipsychotics such as obesity, hyperlipidemia, and hypertension. 100 However, those with nondementia psychoses are likely to be unaffected, or any effect is not clinically relevant. A recent study from Denmark found no cognitive improvement from exenatide in obese patients with clinically stable schizophrenia who were also receiving antipsychotic treatment. The authors noted, however, that 3 months may not have been enough time for cognitive effects to manifest. These subjects were primarily young and middle-aged adults, and none were over 65 years (exenatide group: n = 23, age 37.1 ± 10.6, range 19-65 years; placebo group: n = 22, age 34.5 ± 10.1, range 19-56 years). 101 Pain. Pain syndromes of multifactorial etiologies are highly prevalent, but potentially treatable, causes of excess disability in diabetes patients. 8 GLP-1 RAs may be useful in pain management. Gong and colleagues, in a rat model experiment, found GLP-1 receptors expressed in spinal microglia and upregulated after peripheral nerve injury. 102 When GLP-1 RAs stimulate spinal microglia GLP-1 receptors, beta-endorphins are released and pain diminishes. Exenatide and GLP-1 have been associated with a decrease in pain hypersensitivity via its antinocioceptive effect, an effect mediated by activation of GLP-1 receptors. This effect can be blocked by naloxone, suggesting a modulatory effect on opioidergic pathways. 102, 103 Sleep apnea. Obstructive sleep apnea (OSA) symptoms include snoring, apneas during sleep, and excessive daytime somnolence. 9,10 Untreated, OSA has been linked to hypertension, stroke, congestive heart failure, type 2 diabetes, and depression. OSA is common in mid and later life especially in older obese men. 9, 10 In an RCT of 30 OSA subjects, Amin and colleagues found that the overall apnea-hypopnea index (AHI) for patients treated with liraglutide decreased from 50+ or −32 to 38+ or −30 (p = 0.002). In 70% of the treated group, AHI declined by 44% or 20+ or −12 events per hour, while 30% showed no response to treatment. AHI was 32.6+ or −21 versus 33.2+ or −21 at follow up. Body mass index (BMI) did not change from baseline in either group. 43 In another double blinded RCT (n = 359), Blackman and colleagues found that the greatest reduction in AHI occurred in the first 12 weeks of treatment and minimally thereafter.
In the liraglutide group, AHI was significantly reduced after 32 weeks compared with placebo, independent of age, baseline BMI or OSA severity. Fewer subjects in the liraglutide group met the criteria for OSA diagnosis after treatment. 21 A cross-sectional study by Reutrakyl and colleagues (n = 70) found that increasing OSA was associated with a lower GLP-1 response to a glucose challenge after adjusting for sex, BMI, and glycemic status. 45 In an individual cohort study, Matsumoto and colleagues (n = 96) found higher fasting GLP-1 levels in a severe OSA group, and concluded that this was a compensatory mechanism to increase insulin levels to prevent the development of diabetes, since hypoxia leads to pancreatic damage. 44 The benefit of GLP-1 RAs may therefore increase as the severity of OSA increases.
Effects in bone
Evidence, mostly from basic science research (largely in rodents and in vitro studies), supports the salutary effects of GLP-1 RAs on bone mass and strength reported in human studies; however, the effect on fracture prevention is less clear. Overall, research shows the presence of GLP-1 receptors in bone tissue, especially in osteoblasts, osteocytes, and osteoclasts. [104] [105] [106] [107] [108] [109] The thyroid parafollicular cells, known as C-cells, make a peptide hormone called calcitonin that controls calcium homeostasis. A rise in serum calcium levels stimulates calcitonin secretion from C-cells, which, in turn, inhibits osteoclast-induced bone resorption. The C-cells express GLP-1 receptors; C-cell activation suppresses bone-resorption activity and osteoclast proliferation. [104] [105] [106] The localization of GLP-1 receptors in bone and C-cells has led to various mechanistic studies explaining the antiresorptive and bone-building effects of GLP-1 RAs. These mechanisms include an increase in the activity of osteoblast in response to GLP1R agonist; an increase in the activity of C-cells, which leads to increased levels of calcitonin − a potent inhibitor of osteoclast-induced bone resorption; and improvement in collagen synthesis, bone blood supply, and bone architecture. [106] [107] [108] [109] Reports of the effect of GLP-1 agonist on bone integrity in humans are mixed, ranging from no difference between GLP-1 agonist and other antidiabetic medications, 48, 50 to significant reduction in fractures with liraglutide and a higher rate of fractures with exenatide. 46 The meta-analysis by Mabileau and colleagues analyzed the fracture rate of seven RCTs, and found that GLP-1 receptor agonists (specifically, exenatide in three studies, liraglutide in four) did not significantly reduce incidents of bone fracture in comparison with other antidiabetic medications. 47 Another metaanalysis by Su and colleagues of 16 RCTs using GLP-1 agonists showed that patients receiving liraglutide had a significantly decreased risk of bone fracture, whereas those receiving exenatide had an increased risk of bone fracture. 46 The bone-protective effect of liraglutide was further supported by Iepsen and colleagues in their RCT of 17 obese women randomized to liraglutide or placebo; liraglutide increased bone formation by 16% and prevented the bone loss associated with weight loss. 49 A more recent Bayesean network meta-analysis of many of the same studies found that exenatide was the safest GLP-1 RA to prescribe to reduce fracture risk, followed by dulaglutide, then liraglutide, albiglutide, lixisenatide, and finally semaglutide. 110 Other controlled trials and cohort studies have also shown no significant difference between the GLP-1 agonist group and the control group using other anti-glycemic drugs. 50, 51 However, these studies failed to separate out the effect of different GLP-1 agonist medications (liraglutide versus exenatide versus others). Some of the inconsistency between trials may reflect differences among patients in dose and duration of GLP-1 RAs, type and number of coprescribed medications, severity of diabetes, adherence to diabetes medications, and comorbidity burden. Additional studies are needed to clarify the effect of different GLP-1 receptor agonists on bone formation.
Effects on skin
The evidence for GLP-1 RAs on skin diseases is still very preliminary, with antioxidant, antiinflammatory, and neuromodulatory mechanisms likely responsible for the effects. In a case report by Faurschou and colleagues, psoriasis was found to clear after liraglutide was prescribed for the patient's type 2 diabetes. 52 In another case, the patient was taken off liraglutide and psoriasis returned; two subsequent patients showed lower Psoriasis Area and Severity Index (PASI) scores with treatment. 53 In all four cases, PASI scores lowered immediately. Another report showed plaque clearance with sitagliptin. 111 Glycemic control was not associated with plaque clearance, suggesting another mechanism, perhaps antiinflammatory or the operation of T-cells. 52, 53, 112 Contraindications Important clinically relevant adverse effects (nausea, vomiting, and diarrhea) warrant mention. [113] [114] [115] [116] These adverse effects are extensions of the pharmacological effects of the GLP-1 RAs, especially when they are started at higher doses in frail elders with dementia and multiple coexisting morbidities. Indeed, the side effects of nausea (about 50%, mostly mild and transient) and vomiting (about 10%) were the reasons most commonly reported for discontinuing GLP-1 RAs, which occurs in about 5% of patients. Rarely, the gastrointestinal side effects can lead to dehydration and acute kidney injury. 55 The severity of gastrointestinal side effects depends on both the dose of the GLP-1 RAs and the coprescribed drug, such as metformin. Lowering the dose, using long-acting GLP-1 RAs, and avoiding prodiarrhea/emetic drugs (e.g. metformin or highdose cholinesterase inhibitors) can reduce the incidence of side effects. 116 In a systematic analysis of 32 clinical trials with GLP-1 RAs, Bettge and colleagues found a significant relationship between the risk of nausea and diarrhea and the dose of long-acting GLP-1 RAs; however, this relationship was not significant for vomiting. They also found that concomitant use of metformin significantly increased the odds of nausea (p = 0.04) and vomiting (p = 0.0009). 116 Among all GLP-1 RAs, lixisenatide treatment resulted in the least nausea and vomiting, and semaglutide the most, while all long-acting GLP-1 RAs had lower rates of nausea and vomiting, but higher rate of diarrhea, than short-acting ones. [116] [117] [118] Minor side effects, such as injection site reactions, headache, and nasopharyngitis, rarely led to drug discontinuation and were usually transient. 
Case #2
A 73-year-old man was being followed by his PCP for type 2 diabetes, AD and vascular dementia, low energy, OSA on a continuous positive airway pressure (CPAP) machine, obesity (BMI 43 kg/m 2 ), uncontrolled hypertension (SBP in the 170s mmHg), benign prostatic hyperplasia, hypothyroidism, depression, hyperlipidemia, and seasonal allergic rhinitis. The patient had received a diagnosis of dementia 2 years prior to his first PCP visit. He had been on medications for the rest of his medical conditions for at least 5 years prior to his visit, but the patient and his spouse were unsure of the onset and duration of his conditions. The patient received a once-a-day dose of the following medications: amlodipine 5 mg, losartan 100 mg, hydrochlorothiazide 25 mg, levothyroxine 25 µg, sitagliptin 100 mg, bupropion SR 100 mg, finasteride 5 mg, rivastigmine patch 9.5 mg, simvastatin 20 mg, aspirin 81 mg, and venlafaxine 37.5 mg. Fexofenadine 60 mg was twice daily. Diabetes control was adequate for age, with multiple HbA1c results ranging between 7% and 8%. The patient's BMI remained at 43 kg/m 2 with worsening of his mood (Patient Health Questionnaire-2, PHQ-2), energy, and OSA. MMSE was 22. His Geriatric Depression Scale (GDS) score was zero, but his PHQ-2 screen positive for depression. His SBP remained in the 170s mmHg despite three drugs. His tests showed total cholesterol was 222 mg/dl, LDL was 147 mg/dl, and TSH was 4.28 mIU/l. After a discussion with the patient and his spouse about using GLP-1 RAs for diabetes and weight, the patient was started on subcutaneous exenatide 2 mg per week. His sitagliptin was stopped. Simvastatin was changed to pravastatin, which is hydrophilic and thus has lower cognitive side effects. His venlafaxine was increased to 75 mg daily to further help his depression as well as his mild anxiety symptoms. About 6 months thereafter, the patient's average SBP remained in the 130s mmHg, his BMI remained around 39 kg/m 2 , and his HbA1c levels ranged from 7% to 8%. His MMSE was 17, despite the family reporting an improvement in patient's conversational skills, attention, and memory for people names. His repeat blood tests showed LDL was 103 mg/dl, total cholesterol was 180 mg/dl, and TSH was1.91 mIU/l. Both his GDS and PHQ-2 depression screens were negative. The patient reported being more energetic, sleeping better, and feeling less depressed, prompting discontinuation of his bupropion (which, according to his spouse, worsened his sleep). The patient's family stopped fexofenadine because of abatement of the allergic rhinitis symptoms and concerns about the patient taking too many pills. Sitagliptin was stopped due to overlapping mechanism of action (incretin-based therapeutics) with GLP-1 RAs. The patient continued to tolerate the exenatide with no reports of nausea, vomiting, diarrhea, or abdominal pain (known side effects of exenatide). After up to 15 months of periodic follow-up, the patient remained nondepressed and free of gastrointestinal side effects.
The improvement in HbA1c, weight, lipid profile, and blood pressure in the cases described above (especially in our first patient) is consistent with recent findings from the SUSTAIN-5 Trial, a 30-week multicountry randomized doubleblind, placebo-controlled trial of weekly semaglutide 0.5 or 1.0 mg among 397 diabetes patients on stable basal insulin dose. 120 However, unlike the subjects in the SUSTAIN-5 trial, basal insulin was discontinued in our elderly dementia patient, because of recurrent hypoglycemia episodes.
Clinical implications
A key approach from our clinical experience to reducing the risk of GLP-1 RA-related gastrointestinal side effects is by starting at a low dose (e.g. at 25% of recommended starting dose in frail elders) and by slow titration over months instead of weeks. Another approach is switching to a different GLP-1 RA, as was done for Case #1 above, as the minor pharmacokinetic and dynamic differences between GL-1 RAs may alter an individual patient's risk of adverse effects. The preponderance and variety of these GLP-1 RAs studies (both human and animal, and in vitro) would seem to indicate the need for larger, more rigorous, studies. In particular, more understanding is required of how genetic differences in drug metabolism and GLP-RA effects on renal functions among patients alter the secondary effects of GLP-1 RAs and the mechanisms behind these differences. [121] [122] [123] For example, recent evidence supports the renoprotective effect (via reduced proteinuria and increased natriuresis) of GLP1RAs: a slowing of progression of diabetic kidney disease, and a better preservation of renal functions in diabetes patients with CKD. 122, 123 Future studies are needed to understand the roles of genomics and metabolomics in determining the person-to-person differences in response to GLP1RAs. Data from such studies and others have the potential to inform diabetes clinical practice guidelines vis-à-vis the use of GLP-1RAs.
One limitation of this review is that many of the studies lack the 'gold standard' rigor of RCTs.
The number and variety of effects do, however, appear to indicate a trend. RCTs or database analysis of a large number of patients may be the next step before recommending prescribing changes.
Conclusion
GLP-1 RAs have multiple pleiotropic activities that may help reduce polypharmacy in elderly diabetes patients living with other serious comorbidities. The cases and evidence presented here support the potential for GLP-1 RAs to reduce the incidence or symptoms of those conditions (i.e. PD, osteoporosis, NAFLD, lipoprotein disorders, and hypertension), among other common comorbidities in older adults with diabetes. The effectiveness of GLP-1 RAs in patients with diabetes with impairments in systems other than the endocrine system − cardiovascular, liver, brain, bone, and skin − may reflect the multisystemic role of GLP-1 receptor functions. Inasmuch as the effects of GLP-1 RAs (both positive and negative) are multisystemic, they warrant more rigorous studies on how to harness the positive effects while minimizing the risk of negative effects. The usefulness of GLP-1 RAs in reducing polypharmacy and medication costs in patients with diabetes merits further study in a large randomized, controlled, clinically comparative trial.
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